

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mikio SHOJI et al.

Title: USE OF ANTIBODY

Appl. No.: Unassigned (US Natl. Stage of PCT/JP2004/013397)

Intl. Filing Date: 09/08/2004

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

1020 RECEIVED 08 MAR 2006
TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language document has been provided (Document A1 = Document A2).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 8, 2006

By Stephen B. Maebius

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Unassigned 1001571018
Date Submitted: March 8, 2006		Filing Date	3/8/2006
(use as many sheets as necessary)		First Named Inventor	Mikio SHOJI
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	023312-0122
Sheet	1	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	WO	94/17197	A1	Takeda Chem Ind., Ltd.	08/04/1994	= A1	A
	A3	WO	96/25435	A1	Bayer Corporation	08/22/1996		
	A4	WO	00/77178	A1	Boston Biomedical Research Institute	12/21/2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduct pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , ugust 2000, Vol. 6, No. 8, pp. 916-919.	
	A6	DeMATTOS et al., "Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , July 17, 2001, Vol. 96, No. 15, pp. 8850-8855.	
	A7	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <i>Nature Neuroscience</i> , May 2002, Vol. 5, No. 5, pp. 452-457.	
	A8	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nature Medicine</i> , November 2002, Vol. 8, No. 11, pp. 1270-1275.	
	A9	VEHMAS et al., " β -Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A β Levels in APPswe/PS1 Δ E9 Mice, as Detected by SELDI-TOF-Based ProteinChip® Technology," <i>DNA and Cell Biology</i> , 2001, Vol. 20, No. 11, pp. 713-721.	
	A10	WILCOCK et al., "Intracranially Administered Anti-A β Antibodies Reduce β -Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation," <i>The Journal of Neuroscience</i> , May 1, 2003, Vol. 23, No. 9, pp. 3475-3751.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO codes).

Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.